These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37114121)

  • 1. Case report: anaplastic lymphoma kinase (
    Shigeta N; Murakami S; Yokose T; Miyagi Y; Saito H
    Front Oncol; 2023; 13():1110638. PubMed ID: 37114121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with
    Oya Y; Kuroda H; Nakada T; Takahashi Y; Sakakura N; Hida T
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
    Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
    Front Immunol; 2022; 13():974581. PubMed ID: 36159860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK-Rearranged NSCLC With Concomitant HER2-Mutant Breast Cancer Patient Treated With Alectinib, Trastuzumab, and Pertuzumab: A Case Report.
    Takayasu H; Kata Y; Otsu Y; Inoue S; Kaneko T
    Cureus; 2023 Mar; 15(3):e36711. PubMed ID: 37113357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports.
    Gohara K; Okazaki A; Takeda Y; Iwasa K; Shibata K
    Respir Med Case Rep; 2021; 33():101469. PubMed ID: 34401305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Cameron LB; Hitchen N; Chandran E; Morris T; Manser R; Solomon BJ; Jordan V
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013453. PubMed ID: 34994987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review.
    Gu R; Shi Z; Duan T; Song M
    Onco Targets Ther; 2021; 14():5107-5113. PubMed ID: 34707369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib.
    Zhou Y; Song L; Xu Q; Zeng L; Jiang W; Yang N; Zhang Y
    Lung Cancer; 2022 May; 167():58-64. PubMed ID: 35405360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report.
    Usuda K; Niida Y; Iwai S; Funasaki A; Sekimura A; Motono N; Yamada S; Uramoto H
    Front Oncol; 2020; 10():689. PubMed ID: 32582526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma.
    Dong W; Lei P; Liu X; Li Q; Cheng X
    Front Immunol; 2021; 12():686057. PubMed ID: 34804000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Report: A Case Report of a Histological Transformation of
    Zhang Y; Qin Y; Xu H; Yao Q; Gao Y; Feng Y; Ren J
    Pathol Oncol Res; 2021; 27():637745. PubMed ID: 34257603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
    Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
    Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma.
    Pasau T; Wauters E; Wauters I; Duplaquet F; Pirard L; Pop-Stanciu C; D'Haene N; Dupont M; Vander Borght T; Rondelet B; Ocak S
    Front Oncol; 2022; 12():985446. PubMed ID: 36419902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
    Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Liu YN; Su KY; Chang YL; Wu CT; Liao BC; Hsu CC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
    Oncologist; 2020 Aug; 25(8):702-711. PubMed ID: 32386255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Heo JY; Park C; Keam B; Ock CY; Kim M; Kim TM; Kim DW; Kim SH; Kim YJ; Lee JS; Heo DS
    Thorac Cancer; 2019 Nov; 10(11):2117-2123. PubMed ID: 31509890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
    Saxena P; Singh PK; Malik PS; Singh N
    Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma.
    Baldacci S; Grégoire V; Patrucco E; Chiarle R; Jamme P; Wasielewski E; Descarpentries C; Copin MC; Awad MM; Cortot AB
    Lung Cancer; 2020 Aug; 146():366-369. PubMed ID: 32553554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.